Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Laith Derbas

Interventional Cardiology Orange City, FL Medical Doctor

NPI 1790131779 CMS profile 2777110

1055 Saxon Blvd, Ste 201, Orange City, FL 32763

Open in the dashboard

General payments

$12,133

146 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Laith Derbas of Orange City, FL is reported in the CMS Open Payments database as having received $12,133 across 146 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 63rd percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,104 49
2024 General $3,084 40
2023 General $2,775 25
2022 General $1,321 21
2021 General $603 8
2020 General $246 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laith Derbas
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Laith Derbas were reported at $4,104. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Laith Derbas Interventional Cardiology median Middle half National median
2019 $0 $1,097 $329–$3,048 $163
2020 $246 $473 $161–$1,480 $114
2021 $603 $677 $233–$1,827 $132
2022 $1,321 $978 $333–$2,724 $149
2023 $2,775 $1,136 $382–$2,986 $160
2024 $3,084 $1,181 $395–$3,326 $164
2025 $4,104 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Boston Scientific Corporation $3,084 28 payments
  2. Medtronic, Inc. $2,121 26 payments
  3. Abiomed $1,577 14 payments
  4. Edwards Lifesciences Corporation $1,347 18 payments
  5. Abbott Laboratories $1,055 12 payments
  6. Cardiovascular Systems Inc. $432 6 payments
  7. Inari Medical, Inc. $402 3 payments
  8. Penumbra, Inc. $248 3 payments
  9. Teleflex LLC $217 3 payments
  10. Philips Electronics North America Corporation $185 5 payments
  11. Other $1,464 28 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $9,814 136 payments
  2. Grant $1,421 2 payments
  3. Travel and Lodging $848 6 payments
  4. Education $51 2 payments
Products named General payments · program years 2020–2025
  1. COREVALVE EVOLUT R $1,817 19 payments
  2. Impella $1,186 9 payments
  3. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $765 10 payments
  4. CT THROMBECTOMY SYSTEM KIT $402 3 payments
  5. FLOWTRIEVER CATHETER, S $402 3 payments
  6. WATCHMAN Access System $355 7 payments
  7. WATCHMAN FLX $309 2 payments
  8. Stingray $303 3 payments
  9. Indigo System $248 3 payments
  10. AVVIGO Guidance System $233 5 payments
  11. Other $4,486 76 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

21

Median for Interventional Cardiology: 2,236

Drug cost

$190

Median for Interventional Cardiology: $380,412

Branded share of claims

100%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 21 $190

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Records

146 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record